biostudies-literatureMolnar MZNational Kidney FoundationNIDDK NIH HHSNIAID NIH HHSNational Institutes of HealthMerck Sharp and Dohme599-609https://www.ebi.ac.uk/biostudies/studies/S-EPMC8968853biostudies-literatureUnknown22(2)Kidney transplantation (KT) from deceased donors with hepatitis C virus (HCV) into HCV-negative recipients has become more common. However, the risk of complications such as BK polyomavirus (BKPyV) remains unknown. We assembled a retrospective cohort at four centers. We matched recipients of HCV-viremic kidneys to highly similar recipients of HCV-aviremic kidneys on established risk factors for BKPyV. To limit bias, matches were within the same center. The primary outcome was BKPyV viremia ≥1000 copies/ml or biopsy-proven BKPyV nephropathy; a secondary outcome was BKPyV viremia ≥10 000 copies/ml or nephropathy. Outcomes were analyzed using weighted and stratified Cox regression. The median days to peak BKPyV viremia level was 119 (IQR 87-182). HCV-viremic KT was not associated with increasAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsAssociation of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation.PMC8968853K24AI146137R01DK070869R01 DK070869K24 AI146137Shah MMolnar MZBlumberg EChung RTSchaubel DESise MEBhalla ABloom RDAzhar ATrofe-Clark JElias NPotluri VSBinari LAReese PPTalwar MForbes RCSawinski DBesharatian BConcepcion BPStrohbehn IABalaraman VShaffer DGoldberg DSEason JDfalseAssociation of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation.Kidney transplantation (KT) from deceased donors with hepatitis C virus (HCV) into HCV-negative recipients has become more common. However, the risk of complications such as BK polyomavirus (BKPyV) remains unknown. We assembled a retrospective cohort at four centers. We matched recipients of HCV-viremic kidneys to highly similar recipients of HCV-aviremic kidneys on established risk factors for BKPyV. To limit bias, matches were within the same center. The primary outcome was BKPyV viremia ≥1000 copies/ml or biopsy-proven BKPyV nephropathy; a secondary outcome was BKPyV viremia ≥10 000 copies/ml or nephropathy. Outcomes were analyzed using weighted and stratified Cox regression. The median days to peak BKPyV viremia level was 119 (IQR 87-182). HCV-viremic KT was not associated with increas2022-01-01T00:00:00Z2022 Feb2025-04-05T09:05:27.521Z2025-04-05T09:05:27.521ZS-EPMC89688533461366610.1111/ajt.16834